2016 Japan Pharma Outlook - growth drivers of 12 major Japanese biopharma companies
Japan Pharma Outlook 2016 : JP Giants leaning in for becoming a Speciality Global Pharma
Increasing decline in long listed products sales, and a few success in R & D in the last decade had put JP giants under pressure to refocus on Innovation with specialty therapy area to strengthen their global presence. Eisai Ajinomoto JV, Teva-Takeda partnership for Speciality Generics is the actions in this direction. Fast track approval based on “Sakigake” designation is the step by PMDA/MHLW to encourage JP Pharmas to research in the area of high unmet medical need/orphan disease where US biotech has taken a successful leap in last decade.
Request a sample copy @ http://www.reportsweb.com/inquiry&RW0001173054/sample .
In innovation space, Nivolumab, Alectinib, Dolutegravir global success again demonstrate ability of JP pharma/university research house to contribute Pharma Innovation, while encouraging regulatory environment for “Regenerative Medicine Drug Development” and “Drug Repurposing” will make Japan front runner in this space. From late stage pipeline/new launch, Mirogabalin approval in Neuropathic Pain, Brintellix Cognition label expansion, Edoxaban uptake in EU, Alectinib uptake in US and ACE-910 approval for hemophilia will decide Japanese Innovator growth in Global market. The biennial price cut scheduled in April-2016 will balance Innovation premium with long listed price cut (Z2 rule) to increase R & D productivity.
In next 3 years, ¥950b drugs will go off patent in Japan- and as happened in 2015, substantial volume growth due to new patent expiry opportunities will help Japanese generic companies to withstand NHI pricing pressure. Consolidation activities like Teva-Takeda JV -will make this growing domestic generic market more competitive and companies with “direct sales model” may fetch upper hand due to less dependence on wholesale distribution channel. Challenging Alimta patent and Evista patent against Lilly in Japan, and Livalo ANDA filing in US by JP Generic companies is indicative of the changing breadth of the JP generic giants from launching generics in Japan to becoming a patent challenger- Intellectual property rights challenging generic company. This is a step towards finding its place against the world generic players in the coming time. Successful launch of Blopress AG, Plavix AG in last few years stamps Authorized Generics as one of the attractive opportunity for Generic players in Japan. Encouraging Uptake of Filgrastim BS and Lantus BS in Japan is indicative of Japan to be the next important market after EU in the next five years for growth of Biosimilar players. In contrast, there is a very slow uptake post launch of Remicade biosimilar (~1% volume share).
View complete report @ http://www.reportsweb.com/japan-pharma-outlook-2016-jp-giants-leaning-in-for-becoming-a-speciality-global-pharma .
Table of Contents:
CHUGAI : Sustainable Growth from Oncology Franchisee is Evident!
-Kadcyla Superiority over Tykerb will increase the market size of 2nd/3rd line breast cancer beyond current levels
- Change in Chugai Roche business agreement- For pipeline drug Global development- and to be the first in Class
Table 1 : DEALS DONE BY CHUGAI PHARMA IN 2013-2014-2015
Chugai :KEY MILESTONES
DAIICHI SANKYO : Upcoming Olmetec Patent Cliff – A Definite Need for Swift R & D Strategy!
- Japan Olmetec patent cliff (2019) manageable through growth from Memary, Nexium and Lixiana
Chart 1: Daiichi Sankyo
Efficacy Results of Mirogabalin vs. Lyrica/Pregabalin
Chart 2:
Daiichi Sankyo
Efficacy comparison of Quizartinib vs. ASP-2215
Chart 3: Daiichi Sankyo
US TRX of each NOAC since launch
Chart 4 aiichi Sankyo
New NOAC share vs. Warfarin- Warfarin still holds >60% share in US
Daiichi Sankyo :KEY MILESTONES
Inquire for DISCOUNT offered on this research @ http://www.reportsweb.com/inquiry&RW0001173054/discount .
Contact [email protected] for more details, call us at +1-646-491-9876
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).